Edward J. Tanenbaum

The anti-myeloma effects of the selective JAK1 inhibitor (INCB052793) alone and in combination in vitro and in vivo

Saurabh Patil, Haiming Chen, J. Berenson, 2019, Annals of Hematology.

Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells.

N. Xu, T. Spektor, Saurabh Patil, 2019, Leukemia research.

The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker

Saurabh Patil, Haiming Chen, J. Berenson, 2018, Expert review of molecular diagnostics.

The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma

Saurabh Patil, E. J. Smith, Haiming Chen, 2018, Targeted Oncology.

The JAK Inhibitor Blocks PD-L1, PD-L2 and CD44 Expression in Multiple Myeloma (MM) and Sensitizes MM Cells to Lenalidomide and Steroids

Haiming Chen, J. Berenson, George Y Tang, 2018, Blood.

The anti-myeloma effects of the selective JAK1 inhibitor (INCB052793) alone and in combination in vitro and in vivo

Saurabh Patil, Haiming Chen, J. Berenson, 2019, Annals of Hematology.

The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma

Saurabh Patil, E. J. Smith, Haiming Chen, 2018, Targeted Oncology.